Evolving Landscape of GIST and Treatment Implications - Beyond c-KIT

Thursday, March 5, 2026

4:00 PM - 5:00 PM MST

Location:101A-C

CE: 1

Moderator(s)

Valerie Grignol, MD

Associate Professor of Surgery
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Carolyn Nessim, MD, MSc, FRCSC, FACS (she/her/hers)

Surgical Oncologist, Associate Professor, Clinician Investigator, CGSO Program Director
The Ottawa Hospital, University of Ottawa, Ottawa Hospital Research Institute
Ottawa, Ontario, Canada

This dynamic session delves into the rapidly evolving landscape of gastrointestinal stromal tumor (GIST) management, with emphasis on practice-changing data and the surgeon’s increasingly pivotal role. Participants will explore recent advances in molecular subtyping, new therapeutic strategies, and the impact of emerging clinical evidence in shaping individualized care plans for patients with GIST.

Learning Objectives:

Interpret pathology and molecular subtyping reports to formulate individualized treatment plans.
Categorize the current mutation landscape of GIST and align targeted therapies with specific mutations.
Determine which patients are most likely to benefit from extended adjuvant therapy.

Presentations:

4:06 PM - 4:22 PM MST

The Surgeon's Role in GIST Work-Up and Initial Management
Faculty: Andrew M. Blakely, MD – Surgical Oncology Branch / National Cancer Institute / National Institute of Health
4:22 PM - 4:38 PM MST

Emerging Strategies for Managing Non-KIT Mutant GIST Subtypes
Faculty: Jason K. Sicklick, MD, FACS, FSSO (he/him/his) – Moores Cancer Center | UC San Diego Health
4:38 PM - 4:54 PM MST

Adjuvant Therapy for GIST- How Long and What Next?
Faculty: Suzanne George, MD (she/her/hers) – Dana-Farber Cancer Institute